TAK‑653 (Osavampator)
Selective AMPA-receptor positive allosteric modulator (ampakine). Takeda-developed antidepressant candidate that met its Phase 2 primary endpoint in depression.
Pharmacology
Contents
WHAT IS TAK-653 (OSAVAMPATOR)?
Detailed overview
TAK-653 (osavampator, development code NBI-1065845) is a selective AMPA-receptor positive allosteric modulator (PAM) developed by Takeda. Unlike classic ampakines, it has virtually no intrinsic agonist activity: it amplifies signaling only when neurons are already releasing glutamate, by slowing the desensitization and internalization of the AMPA receptor. This strictly glutamate-dependent action underlies its favorable safety profile: in rats it shows roughly a 419-fold safety margin to the convulsant dose, versus the narrow window of older ampakines. Downstream it strengthens BDNF-mTOR signaling and long-term potentiation (LTP), producing a ketamine-like antidepressant effect but without the dissociation associated with ketamine. In healthy volunteers it was well tolerated up to single doses of 18 mg and repeated doses up to 9 mg/day, with no serious adverse events, seizures or convulsions. In the Phase 2 SAVITRI trial it met its primary endpoint in major depressive disorder (as adjunctive treatment); development continues in Phase 3. It is not approved anywhere.
Mechanism
AMPA-PAM (glutamate-dependent)
Half-life
33-48 hours
Onset
Hours (acute cortical), weeks (antidepressant)
Legal status
Investigational, Phase 3, not approved anywhere
Receptor profile
- AMPA receptorStrong
- BDNF / synaptic responseModerate
- Long-term potentiation (LTP)Moderate
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Overstimulation, agitation from amplified glutamatergic (AMPA) signaling
- Headache (the most commonly reported unpleasant effect)
- Sleep disturbance, heightened alertness if dosed late in the day
- Theoretical seizure/convulsion risk in those predisposed to epilepsy (though the preclinical safety margin is wide and no convulsions occurred in human studies)
- Limited human safety data: investigational, unapproved compound, full side-effect spectrum still unknown
- Long half-life (33-48 h) gives a cumulative effect, steady state over several days
Contraindications · 4
- Personal or family history of epilepsy/seizures (theoretical risk from glutamatergic potentiation)
- Avoid combining with other strong glutamatergic or stimulant compounds (overstimulation risk)
- Pregnancy and breastfeeding: no clinical safety data, avoid
- Not an approved drug, investigational; not recommended for self-treatment of major depression without clinical supervision
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats
Hara H, Suzuki A, Kunugi A, et al.
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers
Dijkstra F, et al.
Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
Suzuki A, et al.
TAK-653 Reverses Core Depressive Symptoms in Chronic Stress-Induced Monkey Model
Li L, et al.
FAQ
FAQ
TAK-653 is a drug candidate being developed by Takeda for depression, and it already hit its target goal in an early-stage human trial. It works by boosting brain signaling pathways that are already active, aiming for a fast, ketamine-like mood lift without the dissociative, mind-altering side effects. It has also shown cognitive-sharpening effects in studies and looked safe so far, but it is still in research/clinical trials, not an available product.
Telegram
Have a question about TAK‑653 (Osavampator)?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.